Polytherapy in psychiatry Review article

Article Sidebar

PDF (Język Polski)


Published: Mar 31, 2014
Keywords:
polytherapy, depression, schizophrenia, bipolar disorder, algorithms

Main Article Content

Iwona Patejuk-Mazurek
1. Klinika Psychiatrii, Oddział Fizjoterapii, Warszawski Uniwersytet Medyczny Mazowieckie. 2. Specjalistyczne Centrum Zdrowia im. prof. Jana Mazurkiewicza w Pruszkowie

Abstract

Polytherapy is common therapeutic strategy in treatment of mental illnesses. Algorithms published by psychiatric organizations suggest using monotherapy (e.g. in schizophrenia) and polytherapy (e.g. in bipolar disorder). Moreover, everyday clinical practice and taking care of good functioning of the patient, which are connected with treatment efficacy, are the reasons for combining drugs, which are not indicated in pharmacological standards, but which are supported by case reports, receptor mechanisms of action and tolerability of the individual patient. In this article author discussed topics concerning polytherapy in the treatment of mental diseases and usefulness of polytherapy in everyday clinical practice.

Article Details

Issue
Vol 6 No 1 (2014)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr 2013; 11 (1): 82-99.
2. APA Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition (dostęp: 23.03.2014).
3. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10; 85-116.
4. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11 (3): 225-255.
5. Vieta E, Murru A, Pueyo MJ. Guideline for the treatment of bipolar disorders in Catalonia (dostęp: 26.03.2014).
6. Chang JS, Ahn YM, Park HJ, Lee KJ, Kim SH, Kang UG, Kim YS. Aripiprazol augmentation in clozapine-treated patients with refraktory schizophrenia: an 8-week, randomized, double-blined, placebo-controlled trial. J Clin Psychiatry 2008; 69, 720-731.
7. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blinded, placebo-controlled trial. Pharmacopsychiatry 2008; 41: 24-28.
8. Zalecenia w sprawie stosowania leków przeciwpsychotycznych II generacji (dostęp: 26.03.2014).
9. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2011.
10. Łoza B, Czernikiewicz A. Pierwszy ogólnopolski konsensus na temat leczenia zaburzeń dwubiegunowych. Neuropsychiatria. Przegląd Kliniczny 2011; 3 (2): 53-59.
11. Łoza B, Czernikiewicz A, Patejuk-Mazurek I, Roszkowska A, Britmann J, Grzesiewska J, Mosiołek A. Politerapia zaburzeń depresyjnych. Preferencje polskich psychiatrów. Psychiatria 2007; 4(3): 97-104.
12. Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risk. CNS Drugs 2011; 25: 383-399.
13. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jorgensen HA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009; 16: 9-24.
14. Weinmann S, Koesters M, Becker T. Effects of implementation of psychiatric guidelines on provider performance and patients outcome: systematic revive. Acta Psychiatr Scand 2007; 115: 420-433.
15. Thase M. What role do atypical antipsychotic drug have in treatment-resistant depression? J Clin Psychiatry 2002; 63: 95-103.
16. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
17. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004; 65: 1377-1388.
18. Tungaraza TE, Gupta S, Jones J, Poole R, Slegg G. Polypharmacy and high-dose antipsychotic regimes in the community. The Psychiatrist 2010; 34: 44-46.
19. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a metaanalysis of randomized controlled trials. Schizophr Bull 2009; 35: 443-457.
20. Centorrino F, Goren JL, Henen J, Salvatore P, Keller JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risk versus benefits. Am J Psychiatry 2004; 161: 700-706.
21. Centorino F, Cincotta SL, Talamo A, Fogarty KV, Guzzetta F, Saadeh MG, Salvarore P, Baldessarini RJ. Hospital use of antipsychotic drugs: polytherapy. Comprehensive Psychiatry 2008; 49: 65-69.
22. Bartyzel M, Łoza B, Mosiołek A. Neuroleptyki atypowe: zasady doboru u pacjentów leczonych w Klinice Psychiatrii AM w Lublinie. Badania nad Schizofrenią 2003; 4: 11-16.
23. Patejuk-Mazurek I, Łoza B, Polikowska M, Pawełczak P. Kwetiapina – przydatność w praktyce psychiatrycznej. Neuropsychiatria. Przegląd Kliniczny 2011; 3(1): 20-24.
24. Łoza B. Vademecum kwetiapiny. Neuropsychiatria. Przegląd Kliniczny 2013; 5(2): 103-111.